GlobeNewsWire
12 Jun 2026, 00:00 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
4 claims · each scored for market impact
The Phase III ESLIM-02 study of sovleplenib met its primary endpoint, showing a 66% durable response rate versus 15% for placebo in wAIHA patients. — Strong positive clinical data in a Phase III trial significantly increases the probability of regulatory approval and future commercial success.
+0.80The China National Medical Products Administration (NMPA) has accepted and granted priority review of the New Drug Application (NDA) for sovleplenib. — Priority review accelerates the timeline to potential market entry and revenue generation in the Chinese market.
+0.60Sovleplenib demonstrated a favorable safety profile with fewer Grade ≥3 adverse events compared to the placebo group (43% vs 59%). — A clean safety profile reduces the risk of regulatory rejection or restrictive labeling upon approval.
+0.40Continue reading
6 related stories
Search tags
The drug showed efficacy in patients who had previously received rituximab therapy, maintaining a 69% durable response rate. — Expanding the addressable market to include refractory patients increases the potential peak sales of the drug.
+0.30Which stocks this story touches
The company announced positive Phase III trial results for sovleplenib and received priority review from the NMPA.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
Benzinga
9h ago
